CureDuchenne Honors Dr. Brenda Wong from Cincinnati Children’s Hospital with CureDuchenne Cares Award
CureDuchenne honored Dr. Brenda Wong from Cincinnati Children’s Hospital Medical Center with the CureDuchenne Cares Award for her outstanding contributions to providing the best standard of care for Duchenne patients and her team’s active involvement in clinical trials for promising Duchenne therapies.
Dr. Wong is the Director of the Comprehensive Neuromuscular Center at Cincinnati Children’s Hospital Medical Center and Professor of Pediatrics and Neurology at the University of Cincinnati. Dr. Wong and the various specialists at the Comprehensive Neuromuscular Center have been delivering state of the art coordinated interdisciplinary care for many patients with Duchenne Muscular Dystrophy from various states in the U.S. and other countries. Dr. Wong and her clinical research team has been actively engaged in various clinical trials of promising therapeutics for Duchenne patients. She is also very involved with the Duchenne community to strive to improve the care and outcome of boys and young men with Duchenne.
“Dr. Wong brings a positive force to improve the lives of those with Duchenne,” said Debra Miller, founder and CEO of CureDuchenne. “She believes children can live happy, productive lives despite their disease. The fact that hundreds of families across the U.S. fly cross-country to see Dr. Wong is a testament to how much she helps our children. Dr. Wong and her team have done so much for Duchenne boys and their families. We are delighted to honor her with the CureDuchenne Cares Award.”
The CureDuchenne Cares Award celebrates the contributions of individuals, organizations and companies that positively impact the lives of those with Duchenne muscular dystrophy. The award was presented to Dr. Wong at the Napa in Newport Wine Auction on February 28 at the Balboa Bay Resort in Newport Beach, Calif. The Napa in Newport Wine Auction benefited CureDuchenne and proceeds of the event will fund research to find a cure for Duchenne, a progressive muscle-wasting disease that impacts 1 in 3,500 boys. Boys with Duchenne are usually diagnosed by 5, in a wheelchair by 12 and most don’t survive their mid-20s. Currently, there is no approved treatment for Duchenne.